The global clinical chemistry analyzers market accounted for USD 9.9 billion in 2016 and is expected to grow at a CAGR of 5.5% during the forecast period. The increasing prevalence of chronic diseases, such as diabetes, is predicted to be one of the high impact rendering drivers of this market. This subsequent increase in disease prevalence has triggered companies to produce advanced analyzers at a large scale, to aid in diagnosis. Consequently, the high need for chemistry analyzers led to an unprecedented growth in new market entrants, resulting in high competition.
The technological innovations in clinical chemistry analyzers have led to early disease detection and specialized diagnosis in the areas of oncology, gynecology, & endocrinology and enabled testing on a larger scale. The advancements comprise advanced modeling & parameter estimation, better resolution, improved pattern recognition, computer-assisted interpretation, and artificial intelligence.
U.S. clinical chemistry analyzers market, by test, 2014 - 2025 (USD Million)
The benefits of abovementioned advancements and automated analyzers are automatic data acquisition, greater process control allowing real-time automation, efficient parameter monitoring, and automatic variable adjustment. These tools also offer analysis of wide range of samples and facilitate immediate generation of results, reflecting their potential applications in intensive care unit, outpatient clinics, and emergency as well as surgical wards in future. These benefits are estimated to drive physician preference for these analyzers, thus creating high potential opportunities for growth during the forecast period.
Reagents accounted for the largest share in the product segment in 2015. The substantial share is predicted to be a consequence of wide array of reagents present in the market, catering to different requirements of clinicians. These reagents predominantly include enzymes, substrates, specific proteins, electrolytes, lipids and others, which are imperative to obtain accurate results in analytical procedures.
In addition, reagents are believed to be highly cost efficient, possess optimum sensitivity, linearity, and precision, which thereby, ensures minimized performance variation. The aforementioned benefits are predicted to be highly responsible for encouraging clinicians to use reagents for accurate diagnosis.
Global clinical chemistry analyzers market share, by product, 2016
Basic MetabolicPanel (BMP) held a dominant share of the test segment in 2015, as a consequence of growing prevalence of lifestyle-induced diseases, such as obesity and other metabolic abnormalities. Rising importance of and awareness regarding point-of-care testing is also one of the key contributing factors toward the segment share. BMP comprises a set of tests that provide clinical information pertaining to problems caused by chemical imbalance in the body to the medical examiners.
The associated benefits with this test have resulted in high acceptance of the same, thereby widening the segment share over the years. Moreover, BMP is increasingly being used and accepted in wide array of applications, such as in newborn screening, which facilitates early detection of congenital genetic as well as metabolic disorders. According to a research paper published in NCBI, it possesses the ability to detect 30 inherited metabolic disorders in a single dried filter paper blood spot.
Hospitals dominated the end-use segment in 2016, owing to the high patient volume, frequent readmissions, and large sample volumes. Moreover, supportive infrastructure facilitates successful diagnostic procedures, thus, resulting in the higher share of hospitals. The increasing number of government initiatives aimed at promoting efficient diagnostic facilities to generate quick results and improve overall efficiency also serves as key contributing factors to the substantial share of the segment.
In addition, in the current scenario, hospitals are increasingly inclined toward acquiring fully automated systems with built-in quality-assurance capabilities, possessing the ability to process large number of samples. These factors are estimated to exert positive influence on the segment growth.
In 2016, North America held the substantial share of the clinical chemistry analyzers market. The supportive government initiatives and high implementation of practice guidelines released by healthcare organizations present across this region are some of the key factors responsible for the high share registered by this region.
Due to increase in outsourcing of manufacture of these analyzers to Asia Pacific countries, such as India and China, this region is anticipated to grow at an exponential rate during the forecast period. Furthermore, high R&D investment by the global players and presence of unexplored opportunities in this region serve as high growth rendering drivers.
Some of the key market participants are F.Hoffmann La Roche; Thermo Fisher Scientific, Inc.; Johnson & Johnson; and Siemens AG. The aforementioned companies are extensively undertaking new and advanced product development activities, collaborative strategies, and mergers & acquisitions, leading to significant growth in this sector.
For instance, in January 2017, Roche launched cobas m 511, integrated hematology analyzer. This product was made available in many countries following the European approval system (CE mark). This product was launched to expand their hematology testing capabilities.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, UK, Germany, Japan, China, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
Segments Covered in the Report
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the clinical chemistry analyzers market on the basis of product, test, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Test Outlook (Revenue, USD Million, 2014 - 2025)
Basic Metabolic Panel
Thyroid Function Panel
Specialty Chemical Tests
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Academic Research Centers
Regional Outlook (Revenue, USD Million, 2014 - 2025)
The Middle East and Africa
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.